Larry focuses on the objective and maintains the opportunity to financially collect all his intellectual values and scientific expertise through the prizes obtained in shares.
as I expected the market tries to set the support in the $ 1.60 area with a few volumes and then launch the title over. the key passages are 1.64 and 1.84; the latter is the most important because it is a point of conversion options in shares for 1.5 million shares and expiring at the end of May 2019, while 1.84 $ for 1 million shares expiring in May 2020. we know very well that 'interest in having actions by managers is the prize and the only opportunity to achieve the extraordinary economic compensation for all they have produced, so they are the first to have interest that materializes and is reevaluated. in this last session there was a timid attempt to overtake 1.64, but as predictable the lower level was immediately restored. the current price is the same set that damn August 8 following the news of partnership with Acadia so technically we can understand even more clearly, that in these four months the market was managed and manipulated without changing substantial positions, if not those that off-market run by Landstead, which I remember is still very present in Neuren, which will reschedule agreements in May 2019.
the time frame is well defined with clear indication that by May we will have substantial changes. in the meantime, on January 9th, Acadia will present itself to the sophisticated biotech world ( https://finance.yahoo.com/news/acadia-pharmaceuticals-present-37th-annual-140000084.html ) probably with news on his path of active experimentation and with what will start in the second half of 2019 and that concerns us directly. in the meantime, Acadia has just over 300 million dollars to spend and we'll see how soon. the most logical hypothesis, by virtue of the exclusive negotiation period in place, is that this money serves this purpose. always by logic and rationality there is the possibility that Acadia tries to buy Neuren even if for years it has worked and collaborated with the major shareholders of Neuren to guarantee a sort of armor. in addition, not to be excluded a priori, the possibility that Acadia is forced to buy Neuren because then the same object of acquisition that more and more strong rumors foresee the eventuality. it is also possible and very interesting that those who aspire to incorporate Acadia try to get there through Neuren, which in fact has a lot of content that Acadia needs immediately, but with 2591 also for the future.
the picture from my point of view is much more exciting than they have made us believe these last 4 months.
- Forums
- ASX - By Stock
- Ann: Final Director's Interest Notice
Larry focuses on the objective and maintains the opportunity to...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$16.33 |
Change
-0.240(1.45%) |
Mkt cap ! $2.087B |
Open | High | Low | Value | Volume |
$16.49 | $16.62 | $15.60 | $11.97M | 733.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 403 | $16.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.42 | 1763 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 403 | 16.310 |
1 | 4130 | 16.240 |
2 | 1375 | 16.220 |
2 | 1763 | 16.200 |
1 | 1763 | 16.160 |
Price($) | Vol. | No. |
---|---|---|
16.420 | 1763 | 1 |
16.470 | 1763 | 1 |
16.500 | 100 | 1 |
16.510 | 1763 | 1 |
16.550 | 1763 | 1 |
Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, MD & CEO
Charles Armstrong
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online